Decoy Therapeutics Inc
salariuspharma.comWhat Do They Do?
Develops peptide-conjugate antiviral candidates for patients at risk from viral diseases, alongside small-molecule cancer drugs and peptide-based protein degraders.
10-K for FY2025, filed Mar 31, 2026We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through…View ↗
The Merger (as defined below) combines our complementary approaches to create a comprehensive drug development platform. The Decoy IMP³ACT…View ↗
We plan to integrate SP-3164 to expand our opportunities in creating a novel class of peptide conjugates called peptide-based proteolysis…View ↗
We intend to leverage the proprietary compound SP-3164, which binds to the E3 ligase complex CRLCBRN, together with our peptide engineering…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$2.4MView ↗
- ▲ +148% (Loss)
- vs −$957.8K in Q2 FY2025
-
Apr 2, 2026
Regains Nasdaq minimum bid-price compliance
Nasdaq confirmed continued-listing compliance, with a one-year monitoring period.
Sources
8-K, filed Apr 2, 2026
On March 31, 2026, the Hearings Panel confirmed that the Company has regained compliance with Minimum Bid Price Requirement and all other…View ↗
A broader therapeutic focus
The older report focuses on small-molecule inhibitors and protein degraders for cancers; the latest centers on peptide-conjugate antivirals and adds peptide-based degraders, while still carrying forward legacy small-molecule candidates.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Mar 31, 2026Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with…View ↗
We are a pre-clinical stage biotechnology company focused on advancing our pipeline of peptide conjugate therapeutics engineered through…View ↗
The Merger (as defined below) combines our complementary approaches to create a comprehensive drug development platform. The Decoy IMP³ACT…View ↗
We plan to integrate SP-3164 to expand our opportunities in creating a novel class of peptide conjugates called peptide-based proteolysis…View ↗
Loading...
